Research programme: erythrocyte encapsulated anticancer therapeutics - ERYtech PharmaAlternative Names: ERY-ADI; eryadi; Gr-RNAi
Latest Information Update: 19 Oct 2015
At a glance
- Originator ERYtech Pharma
- Class Antineoplastics
- Mechanism of Action Amino-acid-modulators; Cytokine inhibitors; Macrophage inhibitors; RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer